NEW YORK – Proteomics firm Somalogic is exploring quantum biosensing technology under a $1 million grant from the National Science Foundation's Convergence Accelerator program.
The effort, which involves collaborators at the University of Chicago, University of California, Los Angeles, University of California, Santa Barbara, and University of Washington could allow the company to explore more portable applications of its SomaScan technology while also potentially improving the specificity of its proteomic measurements, said Jason Cleveland, principal fellow at Somalogic.